OKLAHOMA CITY, March 11, 2023 — Cytovance Biologics and Phenotypeca Limited (Phenotypeca), a research and development organization with proprietary yeast expression technology that provides key advantages in recombinant protein manufacture, have entered into an agreement to provide optimized Saccharomyces cerevisiae strains for biopharmaceutical manufacturing.

Oklahoma City, Oklahoma, April 23, 2020 – Cytovance® Biologics, a USA-based contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”) announced today that it has entered into a collaboration agreement with Akshaya Bio, Inc., a Canadian development stage biotechnology company (“Akshaya”) to provide rapid access to clinical

OKLAHOMA CITY, Nov. 28, 2017 (GLOBE NEWSWIRE) –– Cytovance Biologics, Inc. (Cytovance), a leading full-service contract development and manufacturer of mammalian and microbial biologics, today announced that it has been chosen by Bexion Pharmaceuticals Inc. (Bexion) to manufacture the protein component and active ingredient of Bexion’s first clinical compound, BXQ-350. An ongoing supply of this

EDMONTON, ALBERTA, December 7, 2016 – OncoQuest Inc. (“OncoQuest’), a biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced that it has entered into an Antibody Manufacturing Development Program with Cytovance Biologics (Oklahoma City, OK, USA) for its oregovomab antibody product. Supported by recent positive interim

Oklahoma City, OK – November 17, 2015– Cytovance® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE, NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel. Under the terms of the Agreement,